SVB Leerink Maintains Outperform on Globus Medical, Raises Price Target to $96
SVB Leerink analyst Richard Newitter maintains Globus Medical (NYSE:GMED) with a Outperform and raises the price target from $88 to $96.
Needham Maintains Buy on Globus Medical, Raises Price Target to $92
Needham analyst David Saxon maintains Globus Medical (NYSE:GMED) with a Buy and raises the price target from $82 to $92.
Globus Medical Sees FY21 Adj. EPS $1.89-$2.00 vs $1.89 Est., Sales $925M-$950M vs $926.78M Est.
The Company today increased guidance for full year 2021 net sales from $925 million to $950 million and non-GAAP diluted earnings per share of $1.89 to $2.00.
Globus Medical Q2 Adj. EPS $0.56 Beats $0.44 Estimate, Sales $251.02M Beat $224.64M Estimate
Globus Medical (NYSE:GMED) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate of $0.44 by 27.27 percent. This is a 700 percent increase over earnings of $0.07 per share from the same
Earnings Scheduled For August 4, 2021
Companies Reporting Before The Bell
• UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter.
Unusual Options Activity Insight: Globus Medical
Globus Medical (NYSE:GMED) shares experienced unusual options activity on Tuesday. The stock price moved up to $82.88 following the option alert.
The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam’s Clinical Collaboration, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 29)
Globus Medical Reports Completed 20K Procedures Using Its Excelsius GPS Robotic Navigation System
Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced that over 20,000 spine procedures have been performed utilizing the ExcelsiusGPS® Robotic
The Daily Biotech Pulse: Priority Review For Amgen’s Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 7)